Microbot Medical (MBOT)
(Delayed Data from NSDQ)
$0.88 USD
+0.02 (1.95%)
Updated Apr 26, 2024 03:54 PM ET
After-Market: $0.88 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MBOT 0.88 +0.02(1.95%)
Will MBOT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MBOT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MBOT
Microbot Medical (MBOT) Files IDE to Start Human Clinical Study
Microbot Medical (MBOT) Announces Positive GLP Study Results
MBOT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Microbot Medical Inc. (MBOT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Other News for MBOT
Microbot Medical Outlines Regulatory Goals and Investor Cautions
Analysts Are Bullish on Top Healthcare Stocks: Halozyme (HALO), Cognition Therapeutics (CGTX)
Microbot Medical Shares Status Following Recent Geopolitical Events
Microbot Medical operations remain on track amid Middle East tensions, shares up
Microbot says activities continue without interruption amid geopolitical events